Univax reaches first product milestone

Univax Biologics Inc. (UNVX) filed its first product license application with the FDA, to market WinRho SD for treatment of idiopathic thrombocytopenic purpura (ITP), a blood disorder characterized by abnormally low platelet levels. The primary indications for WinRho SD include the treatment

Read the full 494 word article

How to gain access

Continue reading with a
two-week free trial.